Aortic Valve Regurgitation Clinical Trial
Official title:
Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation: a Real-world, Prospective, Multicenter Study (TRUST TAVR Registry)
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected
Status | Recruiting |
Enrollment | 500 |
Est. completion date | October 2034 |
Est. primary completion date | October 2034 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy. - 2. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form Exclusion Criteria: - 1. Patients who cannot provide informed consent - 2. Patients who are treated with TAVR for aortic stenosis - 3. Patients who are participating in other clinical trials |
Country | Name | City | State |
---|---|---|---|
China | Xijing Hospital | Xi'an | Shannxi |
Lead Sponsor | Collaborator |
---|---|
Xijing Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Combined clinical efficacy outcomes | Combined clinical efficacy outcomes as composed by all-cause mortality, all strokes, any hospitalization | 1 year | |
Secondary | Combined early safety and clinical efficacy outcomes | Composed by all-cause mortality, all strokes, life-threatening or fatal bleeding, major vascular, access-related, or cardiac structural complication, acute kidney injury stage 3 or 4, moderate or severe aortic regurgitation, new permanent pacemaker due to procedure-related conduction abnormalities, conduction block and arrhythmia, surgery or intervention related to the device, any hospitalization, myocardial infarction, any other adverse events | 30 days | |
Secondary | Rate of technical success | Freedom from mortality
Successful access, delivery of the device, and retrieval of the delivery system Correct positioning of a single prosthetic heart valve into the proper anatomical location Freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication |
at exit from procedure room | |
Secondary | Rate of device success | Technical success
Freedom from mortality Freedom from surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication Intended performance of the valve (mean gradient<20mmHg, and less than moderate aortic regurgitation) |
discharge or 30 days | |
Secondary | Combined clinical efficacy outcomes | Combined clinical efficacy outcomes as composed by all-cause mortality, all strokes, any hospitalization | 2 years, 3 years, 4 years | |
Secondary | Rate of all-cause mortality | 5years and 10years | ||
Secondary | Valve-related long-term clinical efficacy | Freedom from bioprosthetic Valve Failure (defined as: Valve-related mortality OR Aortic valve re-operation/re-intervention OR Stage 3 hemodynamic valve deterioration)
Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies) Freedom from VARC Type 2-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents, used specifically for valve-related concerns (e.g. clinically apparent leaflet thrombosis) |
5 years and 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05438862 -
Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation
|
N/A | |
Completed |
NCT03644784 -
Protocoled Quantitative Assessment of Aortic Regurgitation Using Videodensitometry in a Multicontinental Trial in Rotterdam, Montreal, Yamaguchi, Segeberg, Amsterdam.
|
||
Recruiting |
NCT04797572 -
Clinical Evaluation of the Free Margin Cusp Sizer (CALIBRATE)
|
N/A | |
Not yet recruiting |
NCT05536310 -
TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease
|
||
Completed |
NCT02375282 -
Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study
|
N/A | |
Completed |
NCT04548726 -
Hemodynamic Matched Comparison of the Balloon-Expandable Transcatheter Heart Valves Myval and Sapien-3 for the Treatment of Aortic Stenosis
|
||
Not yet recruiting |
NCT06455787 -
J-Valve Transfemoral Pivotal Study
|
N/A | |
Completed |
NCT01593917 -
Trifectaâ„¢ Long Term Follow-Up (LTFU) Study
|
||
Recruiting |
NCT05459233 -
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
|
N/A | |
Recruiting |
NCT05902897 -
Aortic or Mitral Valve Replacement With the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis
|
||
Completed |
NCT03807921 -
Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
|
Phase 4 | |
Recruiting |
NCT04464655 -
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
|
||
Recruiting |
NCT05799573 -
CT Scan Sizing for Perceval Sutureless Valve
|
||
Completed |
NCT00636987 -
Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra
|
N/A |